Navigation Links
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
Date:4/20/2009

Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD

SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.

AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Phase I study is designed to obtain safety and proof of mechanism data for AM211.

"There remains a great deal of unmet medical need in asthma and COPD, and we look forward to exploring AM211's potential as a new treatment option," said Isabelle DeArmond, M.D., Vice President Clinical Development. "We may also explore AM211 in other inflammatory diseases based on the safety and proof of mechanism data from our Phase I studies."

DP2 is also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.

"The start of the AM211 clinical studies marks another impressive milestone in our company's short existence. Our small but effective team has been able to bring three distinct molecules into the clinic in less than four years," said Bob Baltera, Amira's Chief Executive Officer. "We look forward to continuing this pace as we advance our next program for idiopathic pulmonary fibrosis toward the clinic."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
2. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
3. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
6. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
7. Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
8. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
9. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
10. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Fla., Dec. 14 Dyadic International, Inc. ... has extended its collaboration with The Scripps Research ... Scripps to re-annotate the genome of Dyadic,s patented ... is a continuation of the successful relationship between ... when Dyadic engaged Scripps to annotate the C1 ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
(Date:12/11/2009)... Dec. 11 Dendreon Corporation (Nasdaq: ... its previously announced public offering have exercised in ... shares of common stock at the public offering ... of the option increases the size of the ... common stock. Dendreon expects to receive net ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
Breaking Biology Technology:Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... 30 Luminex Corporation,(Nasdaq: LMNX ) today ... Partners Healthcare Conference to be held September 5 ... by Patrick J. Balthrop, president and chief,executive officer, ... at 1:30 p.m. Eastern time on Thursday, September ...
... /Xinhua-PRNewswire/ -- Mindray Medical,International Limited (NYSE: MR ... devices in China with a rapidly growing international,presence, ... Co-Chief Executive,Officer, Ms. Joyce Hsu, Chief Financial Officer ... will attend the Merrill Lynch Global,Pharmaceutical, Biotech & ...
... the leading online,source for life science careers ... the 11th edition of the Biotech Bay(TM) ... promotional Hotbed Map and also,functional components to ... development initiatives of Northern California. Novartis Vaccines,and ...
Other Biology Technology:Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference 2Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference 2BioSpace and BayBio Launch 11th Edition of Biotech Bay(TM) Hotbed Map Campaign 2
(Date:12/14/2009)... an international team that has used DNA samples from ... of North America,s woolly mammoths and ancient horses. , ... Sciences professor Duane Froese and his colleagues counters an ... and teeth. That analysis concluded that more than half ... disappeared about 13,000 years ago. , In the ...
(Date:12/14/2009)... as a clean-burning, renewable fuel that could help wean ... caused by ozone, compared with gasoline, especially in winter, ... , Ozone production from both gasoline and E85, ... percent ethanol, is greater in warm sunny weather than ... because heat and sunlight contribute to ozone formation. But ...
(Date:12/14/2009)... to date of the proteins in a species of ... to how similar regeneration could be induced in humans. ... Indiana University-Purdue University Indianapolis and colleagues investigated over three ... type of salamander that has the unique natural ability ... the hope that this knowledge will contribute to a ...
Breaking Biology News(10 mins):Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3IUPUI researchers tackle protein mechanisms behind limb regeneration 2Anthem Life 26 Disability Insurance Company Offers The Healing Book to Help Young Life Insurance Beneficiaries Cope With Losing a Loved One 56277 1Anthem Life 26 Disability Insurance Company Offers The Healing Book to Help Young Life Insurance Beneficiaries Cope With Losing a Loved One 56277 2TOMORROW 3A Lets Get It Done 3A Organizing for America to Host Spanish Language Forum on Health Insurance Reform Now in Tucson with Rep Raul Grijalva 56274 1TOMORROW 3A Lets Get It Done 3A Organizing for America to Host Spanish Language Forum on Health Insurance Reform Now in Tucson with Rep Raul Grijalva 56274 2Fruit Even Healthier Than Thought 3A Study 56271 1
... Medical Institute (HHMI) scientists has peeled back some of the ... selectively to control critical events of development. The new insights ... of Dicer, an enzyme that enables cells to dissect genetic ... January 13, 2005, issue of the journal Science by an ...
... Institute (HHMI) scientists has peeled back some of the mystery ... to control critical events of development. The new insights arise ... Dicer, an enzyme that enables cells to dissect genetic material ... 13, 2005, issue of the journal Science by an HHMI ...
... the University of Minnesota Medical School have discovered a new ... properties of primitive stem cells. , Umbilical cord ... can only produce cells found in blood. The new ... with the characteristics of more primitive stem cells that have ...
Other Biology News:Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease 2Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease 3Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease 4Molecule does more than slice and dice RNA 2Molecule does more than slice and dice RNA 3Molecule does more than slice and dice RNA 4
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
... used to quantitate double-stranded DNA (dsDNA) in solution, ... With this kit, DNA is stained with Hoechst ... VersaFluor or other fluorometer. The kit quantitates dsDNA ... to 5 micrograms per ml and contains Hoechst ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
... microplate readers combines reagent dispensing with fluorescence, ... easy-to-use platform for the complete range of ... and adaptability of the Infinite 200 series ... monochromator (M200) or filter (F200) system and ...
Biology Products: